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ABSTRACT
Objectives: To assess the safety and immunogenicity of two vaccines, MSP142-FVO/
Alhydrogel and MSP142-3D7/Alhydrogel, targeting blood-stage Plasmodium falciparum para-
sites.
Design: A Phase 1 open-label, dose-escalating study.
Setting: Quintiles Phase 1 Services, Lenexa, Kansas between July 2004 and November 2005.
Participants: Sixty healthy malaria-naı ¨ve volunteers 18–48 y of age.
Interventions: The C-terminal 42-kDa region of merozoite surface protein 1 (MSP142)
corresponding to the two allelic forms present in FVO and 3D7 P. falciparum lines were
expressed in Escherichia coli, refolded, purified, and formulated on Alhydrogel (aluminum
hydroxide). For each vaccine, volunteers in each of three dose cohorts (5, 20, and 80 lg) were
vaccinated at 0, 28, and 180 d. Volunteers were followed for 1 y.
Outcome Measures: The safety of MSP142-FVO/Alhydrogel and MSP142-3D7/Alhydrogel was
assessed. The antibody response to each vaccine was measured by reactivity to homologous
and heterologous MSP142, MSP119, and MSP133 recombinant proteins and recognition of FVO
and 3D7 parasites.
Results: Anti-MSP142 antibodies were detected by ELISA in 20/27 (74%) and 22/27 (81%)
volunteers receiving three vaccinations of MSP142-FVO/Alhydrogel or MSP142-3D7/Alhydrogel,
respectively. Regardless of the vaccine, the antibodies were cross-reactive to both MSP142-FVO
and MSP142-3D7 proteins. The majority of the antibody response targeted the C-terminal 19-
kDa domain of MSP142, although low-level antibodies to the N-terminal 33-kDa domain of
MSP142 were also detected. Immunofluorescence microscopy of sera from the volunteers
demonstrated reactivity with both FVO and 3D7 P. falciparum schizonts and free merozoites.
Minimal in vitro growth inhibition of FVO or 3D7 parasites by purified IgG from the sera of the
vaccinees was observed.
Conclusions: The MSP142/Alhydrogel vaccines were safe and well tolerated but not
sufficiently immunogenic to generate a biologic effect in vitro. Addition of immunostimulants
to the Alhydrogel formulation to elicit higher vaccine-induced responses in humans may be
required for an effective vaccine.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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PLoS CLINICAL TRIALSINTRODUCTION
The Plasmodium falciparum parasite is responsible for at least
300 million cases of malaria each year [1], and more than one
million of these cases result in death [2]. Approximately 90%
of these deaths, the majority in children under 5 y of age,
occur in Africa [3,4]. The clinical symptoms and pathology
associated with P. falciparum infection are associated with the
cyclical invasion of erythrocytes, intracellular parasite multi-
plication, and release of parasites by rupture of the infected
cells. A vaccine that interrupted this cycle of infection could
reduce both mortality and morbidity secondary to P.
falciparum infection and would be a valuable resource in the
ﬁght against this disease.
Over time, people living in endemic areas develop
immunity to severe disease due to P. falciparum as a result of
repeated infection [5,6]. This acquired immunity is mediated,
in part, by blood-stage parasite-speciﬁc antibodies [7–9].
Thus, parasite proteins expressed during the blood-stage have
been proposed to be good candidates for inclusion in a
vaccine. The aim of an asexual blood-stage vaccine is to elicit
immune responses that slow or inhibit parasite multiplication
to prevent morbidity, severe disease, and death in residents of
malaria-endemic areas, primarily young children and infants.
P. falciparum’s merozoite surface protein 1 (MSP1) is
synthesized as a ;200-kDa polypeptide. MSP1 is processed
at, or just prior to, merozoite release from the erythrocyte
into smaller fragments that form a noncovalently associated
complex [10]. The C-terminal 42-kDa cleavage product of
MSP1 (MSP142), a major candidate for a blood-stage malaria
vaccine, is composed of two regions: MSP133 and MSP119 [11].
The MSP133 portion is dimorphic. Although the sequence
similarity between the two forms of MSP133 is surprisingly
low (47% identity) within each dimorphic type, the sequence
is highly conserved. The MSP119 domain is largely conserved
between parasite strains [12,13]. Four commonly observed
amino acid substitutions have been identiﬁed in MSP119 in
laboratory lines with several additional polymorphisms in
ﬁeld isolates [13,14]. The MSP142 proteins of the FVO and
3D7 P. falciparum parasite lines cover both dimorphisms in
MSP133 and the more common antigenic diversity in MSP119.
The inclusion of both MSP142-FVO and MSP142-3D7 proteins
in a combination vaccine would, in large part, address the
concerns of generating protective immune responses to a
polymorphic parasite protein.
In studies of natural infection, the majority of the B cell
epitopes have been localized to the highly conserved MSP119
domain [15,16], and the epitopes that induce proliferation of
T cell subsets speciﬁc for MSP142 have been localized to the
dimorphic region of the molecule MSP133 [15,16]. A
combination MSP142-FVO and MSP142-3D7 vaccine may be
essential to prime for, or to boost immune responses, that
would ultimately result in optimal immune responses in
endemic areas.
Previous human trials have evaluated recombinant protein
vaccines based on the C terminus of MSP1. The ﬁrst trial
evaluated fusion proteins of FVO and 3D7 forms of MSP119
with the tetanus toxoid universal T cell epitopes P30P2
formulated on Alhydrogel in a United States population [17].
These vaccines were poorly immunogenic and their admin-
istration resulted in three immediate-type hypersensitivity
reactions, which halted the trial. More recent trials assessed
Editorial Commentary
Background: Generally, adults living in parts of the world where malaria
is common develop protective immunity against the parasite. This
means they may get infected but not become ill as a result. However,
there are individuals, such as pregnant women and children under the
age of five, who are more likely to develop symptoms of malaria due to
no (or reduced) natural immunity. A successful malaria vaccine would
stimulate an individual’s immune system to respond to the malaria
parasite and prevent serious clinical disease. Many different groups are
currently developing potential vaccines. Several candidates are based on
a protein called MSP1 (merozoite surface protein 1) which is found on
the surface of the blood-stage form of the malaria parasite. However, in
nature parasites carry different versions of the MSP1 protein, and ideally
a successful vaccine would bring about immune responses against these
different versions. The researchers carrying out this trial wanted to
compare the safety and immune responses against candidate vaccines
representing two different MSP1 proteins, which covered many different
parasite lines. As a phase 1 trial, the study was carried out in healthy
adult volunteers. Sixty individuals were assigned to receive an injection
of the vaccines, either containing a recombinant protein analogous to
the FVO parasite line (termed MSP142-FVO) or the 3D7 parasite line
(termed MSP142-3D7) at three different dose levels. The trial’s primary
objective was to assess safety, which was done by collecting data on any
abnormal signs or symptoms up to 14 d after each of three vaccinations.
These outcomes were graded and then defined as related to the vaccine
or not. The researchers also looked at antibody levels in participants’
blood against different variants of the MSP1 protein, as well as using in
vitro tests to see whether antibodies from vaccinated individuals could
prevent malaria parasites from growing in lab culture.
What the trial shows: The safety outcomes of the trial showed that the
most common type of side effect experienced by the volunteers was
pain at the injection site. The vast majority of such events were graded
as mild, although there was one single case of a severe event (high levels
of pain experienced by one volunteer at the injection site). There was no
significant association between the chance of side effects and the
vaccine dosage that an individual received. Following vaccination,
antibody levels against the protein on which the vaccine was based were
detected, although these levels dropped over time. The researchers did
not see a strong association between the vaccine dosage that individuals
received and the level of antibody response. However, the two vaccines
when compared seemed to be equally good at raising an immune
response and both caused antibodies to be raised corresponding to
different variants of the MSP1 protein. However, the antibodies raised
did not seem to be particularly effective at preventing malaria parasites
from growing in lab culture.
Strengths and limitations: Strengths of this study include a comparison
of three different dosage levels of the vaccines under study, as well as a
comparison of two vaccines based on the same protein, representing
different parasite lines. Limitations to the study include the small number
of participants, which makes the trial underpowered to detect all but
large differences in side effects between the groups being compared. A
placebo arm was not included in the trial, so it is not possible to be sure
that the numbers of side effects observed here can be attributed to the
vaccines or not. Finally, the procedure for assigning individuals to the
two different vaccines involved alternation, rather than true random-
ization, which could have minimized the risk of bias.
Contribution to the evidence: The trial reported here is an essential
step in vaccine development. The results provide the first evidence
relating to safety for these two vaccines, and do not raise any safety
concerns at this stage. Although the vaccines raised an immune
response, the antibodies raised did not seem to have much of an effect
on malaria parasites in vitro. While these vaccines are safe, alternative
MSP1 vaccine formulations anticipated to bring about a greater immune
response will likely be studied before proceeding to field studies.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
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MSP142/Alhydrogel Vaccinesrecombinant MSP142-3D7 (FMP-1) formulated with GlaxoS-
mithKline Biologicals’ proprietary adjuvant AS02A in the
United States and Africa (Kenya and Mali) [18–21]. In all
populations, FMP1/AS02A was safe and immunogenic. In the
malaria-naı ¨ve population, biologically active antibodies and
antigen reactive T cells were induced [19]. There have been
no trials to date evaluating the immunogenicity of MSP142-
FVO or comparing the speciﬁcity of the human responses to
the two dimorphic forms of MSP142.
The Malaria Vaccine Development Branch (MVDB), Na-
tional Institutes of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH) manufactured two
individual clinical grade recombinant MSP142 proteins
derived from the FVO and 3D7 parasite lines of P. falciparum
with the ultimate aim of using them in a combination vaccine.
Each MSP142 protein was individually formulated on Alhy-
drogel (Brenntag Biosector, Denmark), an aluminum hydrox-
ide gel, to produce the vaccines, MSP142-FVO/Alhydrogel and
MSP142-3D7/Alhydrogel. This paper compares the safety and
immunogenicity of these individual formulations when tested
in a healthy United States adult population.
METHODS
Participants
Sixty healthy volunteers, 18–48 y of age, were recruited from
the Lenexa, Kansas area. Written informed consent was
obtained prior to enrollment. Volunteers were recruited and
consented using a protocol and consent form approved by
the Heartland Institutional Review Board (trial site IRB), the
PATH Human Subjects Protection Committee, and the
NIAID IRB. Volunteers were excluded if they had any of the
following: evidence of clinically signiﬁcant systemic disease;
obesity (body mass index  35); pregnancy or breast-feeding;
serological evidence of human immunodeﬁciency virus
infection, chronic hepatitis B or hepatitis C infection; current
medication with corticosteroids or immunosuppressive
drugs; immunization with a live vaccine 4 wk prior to entry
or a killed vaccine 2 wk prior to entry into the study; prior
malaria infection; previous receipt of a malaria vaccine; travel
to a malaria-endemic country 12 mo prior to study enroll-
ment; or planned travel to a malaria-endemic country during
the course of the study. All females had a urine ß human
chorionic gonadotropin test at screening and immediately
prior to each vaccination.
Intervention: Purification and Characterization of
Clinical Grade MSP142 Antigens and Vaccine
Preparation
The expression, refolding, and puriﬁcation of E. coli-pro-
duced MSP142-FVO (lot WRAIR0997) and MSP142-3D7 (lot
WRAIR0984) antigens was performed at the Walter Reed
Army Institute of Research, Pilot Bioproduction Facility,
Silver Spring, Maryland in accordance with current Good
Manufacturing Practices (cGMP). Each protein underwent
comprehensive quality control analysis to ensure purity,
identity, and integrity. MSP142-FVO and MSP142-3D7 re-
combinant proteins are highly puriﬁed 42,173-Da and 44,236-
Da polypeptides, respectively, which correspond to the
external domain of MSP142 from the P. falciparum FVO and
3D7 lines.
EcMSP142-FVO and EcMSP142-3D7 were each expressed as
histidine-tagged fusion proteins from synthetic genes, cloned
into pET-24d or pET-24a (Novagen, http://www.novagen.com),
respectively, and transformed into BL21 (DE3) E. coli
(Invitrogen, http://www.invitrogen.com). Following E. coli
fermentation in deﬁned medium and isopropyl-b-D-thioga-
lactopyranoside induction, each protein was extracted from
solublized inclusion bodies, and EcMSP142-FVO underwent
an initial puriﬁcation by reverse-phase chromatography. This
product or the extracted EcMSP142-3D7 was subjected to
nickel-afﬁnity chromatography, refolding by rapid dilution,
and further puriﬁed by anion-exchange chromatography and
size-exclusion chromatography (L. B. Martin, et al., unpub-
lished data). Both antigens were supplied in sterile phosphate
buffered saline (PBS [pH 7.4]) containing 0.2% polysorbate
80. For EcMSP142-FVO, the ﬁnal purity (percentage in a
single band by SDS-PAGE and densitometry) was ;95.0%,
with a host cell protein impurity level of 0.036% and
endotoxin level (as measured by the Limulus amoebocyte
lysate gel clot assay) of 0.12 endotoxin units (EU)/mg. The
results for EcMSP142-3D7 were ﬁnal purity ;97.4%, host cell
protein impurity level of 0.096%, and endotoxin level of 6.7
EU/mg.
Clinical grade MSP142-FVO or MSP142-3D7 recombinant
protein was adsorbed to Alhydrogel and vialed by the
Pharmaceutical Development Section, NIH. Three lots were
prepared, containing 5, 20, or 80 lg of MSP142-FVO or
MSP142-3D7, and 800 lg of Alhydrogel per 0.5 mL dose. The
formulations were supplied as single-dose vials of a cloudy
suspension, without additional stabilizers or preservatives, in
a sterile saline solution. Each vaccine lot underwent
comprehensive quality control analysis to ensure purity,
identity, and integrity. The continued potency and stability of
the six lots of vaccine stored at 2–8 8C were conﬁrmed by
evaluation of their immunogenicity in mice conducted every
6 mo throughout the course of the trial. Biochemical stability
was evaluated annually.
Intervention: Phase 1 Study Design
An open-label, dose-escalating Phase 1 clinical trial was
designed to evaluate the safety, reactogenicity, and immuno-
genicity of the MSP142-FVO and MSP142-3D7 recombinant
proteins formulated on Alhydrogel in healthy adult volun-
teers. Thirty volunteers received the MSP142-FVO/Alhydrogel
vaccine and 30 volunteers received the MSP142-3D7/Alhy-
drogel vaccine (Figure 1). Rolling recruitment and enrollment
took place to ﬁll the low-dose cohorts prior to the medium-
dose cohort followed by the high-dose cohort. After enroll-
ment to a dose cohort, volunteers were alternatively assigned
to either the MSP142-FVO/Alhydrogel or MSP142-3D7/Alhy-
drogel vaccine group. Ten volunteers were assigned to each of
three dose cohorts (5, 20, and 80 lg) for each vaccine for a
total of six groups (three groups for MSP142-FVO/Alhydrogel
and three groups for MSP142-3D7/Alhydrogel). Volunteers
were vaccinated with a 0.5-mL intramuscular injection in
alternate arms on study days 0, 28, and 180. Escalation to the
next higher dose required approval by an independent safety
monitoring committee.
This study was performed under an investigational new
drug application (BB-IND Number 11635) approved by the
United States Food and Drug Administration. MSP142-FVO/
Alhydrogel and MSP142-3D7/Alhydrogel were considered
separate candidate vaccines contained within one protocol.
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MSP142/Alhydrogel VaccinesThe protocol, amendments to the protocol, informed consent
form, advertisements, and other study-related documents
were approved by the Heartland Institutional Review Board
(trial site IRB), the PATH Human Subjects Protection
Committee, and the NIAID IRB.
Objectives
The goal of this Phase 1 vaccine trial was to demonstrate
safety and immunogenicity of MSP142/Alhydrogel malaria
vaccines in human volunteers. The primary objective was to
determine the frequency and severity of vaccine-related
adverse events for each dose of vaccine. Secondary objectives
assessed and compared the speciﬁc antibody response to
homologous and heterologous MSP142 protein with time.
Outcomes: Assessment of Safety and Tolerability
The primary outcome was to assess the safety and tolerability
of the vaccines. Following each vaccination, the volunteers
were observed for 60 min and then evaluated for evidence of
local and systemic reactogenicity on days 1, 3, 7, and 14 after
each vaccination. Solicited systemic adverse events included
fever (.37.5 8C), headache, nausea, malaise, myalgia, arthral-
gia, and urticaria. Volunteers were asked to keep a diary card
to record oral temperature and any local or systemic adverse
events daily for 6 d following each vaccination. Diary cards
were collected 7 d after each vaccination. An abbreviated
history and physical examination was performed at each
follow-up visit. All abnormal signs and symptoms were
considered adverse events. Each adverse event was graded
Figure 1. CONSORT Flow Chart
Volunteers were enrolled following rolling-recruitment and assigned to one of six groups. Volunteers were alternately placed to receive either the MSP142-FVO/
Alhydrogel or MSP142-3D7/Alhydrogel vaccine after assignment into a dose cohort. Volunteers were seen 1, 3, 7, and 14 d after each vaccination and on days 270
and 364 of the study. Immunologic assessment was carried out on samples obtained on study days 0, 14, 28, 42, 120, 180, 194, 270, and 364. 54 of 60 volunteers
completed the entire study; three were lost-to-follow-up, one withdrew consent, and two did not receive the third vaccination and were followed for safety only.
doi:10.1371/journal.pctr.0020012.g001
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MSP142/Alhydrogel Vaccinesfor severity and assigned causality relative to the study
vaccine using the following terms: deﬁnite, probable, possi-
ble, remote, or unrelated. A complete blood count and white
blood cell differential, as well as serum creatinine, aspartate
aminotransferase, and alanine aminotransferase were per-
formed immediately prior to each vaccination, as well as 3
and 14 d after each vaccination.
Outcomes: Antibody Measurement by Enzyme-Linked
Immunosorbent Assay
Secondary outcomes were enzyme-linked immunosorbent
assay (ELISA) measurements of speciﬁc serum antibodies to
the FVO and 3D7 forms of MSP142, MSP119, and MSP133.A
standardized ELISA protocol was employed for the measure-
ment of anti-MSP142, anti-MSP119, and anti-MSP133 anti-
bodies, representing both the FVO and 3D7 forms of the
proteins, as previously described [22]. A human anti-MSP1
standard was prepared by pooling sera from ten individuals
residing in Mali, a country endemic for P. falciparum malaria.
The standard serum pool was assigned 10,000 ELISA units on
MSP142-FVO, 5,882 ELISA units on MSP142-3D7, 2,800 ELISA
units on MSP119-FVO, and 1,500 ELISA units on MSP119-3D7.
An ELISA unit was approximately equivalent to the recip-
rocal of the dilution giving an optical density (OD) of 1.0. A
volunteer was considered to be a non-responder if a speciﬁc
antibody level was less than 50 ELISA units. Due to the low
titer in the standard serum pool, ELISA unit values for
MSP133 were not assigned.
The expression and puriﬁcation of Saccharomyces cerevisiae-
produced MSP119 and E. coli-produced MSP133 were carried
out by MVDB. ScMSP119–FVO and ScMSP119-3D7 clones
were fermented [23] and puriﬁed essentially as reported
previously [24], except that the anion exchange step was
excluded due to the low endotoxin levels of the yeast
products. ScMSP119-FVO and ScMSP119-3D7 proteins were
supplied in PBS.
E. coli BL21 (DE3) cells transformed with EcMSP133-FVO or
EcMSP133-3D7 plasmids were fermented, inclusion bodies
isolated, and the solubilized inclusion bodies were puriﬁed by
nickel-afﬁnity chromatography [24]. Due to the low solubility
of EcMSP133-FVO, it could not be effectively puriﬁed further
and was supplied in elution buffer containing 4 M guanidine.
EcMSP133-3D7 was further puriﬁed by anion exchange
chromatography and size-exclusion chromatography, as
described for ScMSP119. EcMSP133-3D7 was supplied in PBS
plus 0.2% polysorbate 80.
The puriﬁed ScMSP119 and EcMSP133 recombinant pro-
teins were characterized by reverse-phase HPLC [25], N-
terminal sequencing, electron-spray ionization mass spec-
trometry, SDS-PAGE (reduced and nonreduced), and immu-
noblot essentially as described [24]. The observed results were
similar to those expected for each recombinant protein.
Outcomes: Isotyping of MSP142 Antibodies Using
Suspension Array Technology
Serum samples from volunteers vaccinated with MSP142-
FVO/Alhydrogel or MSP142-3D7/Alhydrogel were assayed for
IgG subclasses against the immunizing antigen using a ﬂow
cytometric suspension array assay. Serum samples were
diluted 1:100 and mixed with microspheres coupled with
the homologous MSP142 antigen (Luminex Corporation,
http://www.luminexcorp.com) in MultiScreen plates (Milli-
pore, http://www.millipore.com). Mouse anti-human IgG iso-
type antibody and a second donkey anti-mouse-IgG
phycoerythrin (PE) labeled antibody (Jackson ImmunoRe-
search, http://www.jacksonimmuno.com) were added to devel-
op the reaction. The mean ﬂuorescence intensity (MFI),
corresponding to the presence of speciﬁc IgG subclasses to
MSP142, was detected by Luminex X-MAP with the software
Bioplex (Bio-Rad, http://www.bio-rad.com).
Outcomes: In Vitro Parasite Growth Inhibition by
Immune IgG and Immunofluorescence with Sera on
Malaria Parasites
The ability of antibodies from vaccinated individuals to
inhibit growth of P. falciparum FVO and 3D7 parasites in vitro
was assessed using a standardized growth inhibition assay
(GIA) as previously described [22]. To ensure that the
inhibitory activity measured was speciﬁc to antibody and
not other serum components, total IgG was puriﬁed from
individual sera obtained on days 0, 42, and 194 using Protein
G columns (Pierce, http://www.pierce.com). Anti-MSP142-FVO
and anti-MSP142-3D7 ELISA units were determined for each
puriﬁed IgG sample (10 mg/mL), and all samples were stored
in small aliquots at 2–8 8C until tested.
Indirect immunoﬂuorescence assay (IFA) of P. falciparum
FVO or 3D7 parasitized red blood cells (RBC, 3%–7%
parasitemia) stained using volunteer sera obtained on day 0
and day 194. Thin smears from bulk parasite cultures were
prepared and stored at  80 8C. The FVO and 3D7 parasite
smears were validated using mouse monoclonal antibodies
1G3 and 4H9/19 speciﬁc for MSP142-FVO and MSP142-3D7
proteins, respectively, and anti-mouse IgG FITC (Zymed,
http://www.zymed.com). After ﬁxation with methanol and
blocking with 10% bovine serum albumin (BSA Fraction V;
Sigma, http://www.sigmaaldrich.com), preimmune (day 0) and
day 194 sera (diluted 1:100) were allowed to react with the
parasite-infected RBC. A positive serum (diluted 1:400) and
negative control (no sera) were included on each slide.
Antibody bound to the parasite was detected with secondary
antibody, anti-human IgG FITC (ICN/CAPPEL, Aurora, Ohio,
United States). The slides were examined with an immuno-
ﬂuorescent microscope (Olympus, http://www.olympus.com)
and photographed using a digital camera (Olympus), and the
smears scored on staining pattern and ﬂuorescence intensity:
0 ¼ negative or diffuse staining; 1 ¼ weak staining with
characteristics of trophozoites, schizonts, or free merozoites;
and 2 ¼ bright staining with characteristics of trophozoites,
schizonts, or free merozoites. The day 194 sera with positive
immunoﬂuorescence were compared with corresponding day
0 sera for speciﬁcity of reactions to the parasitized RBC.
Sample Size
The sample size required in each treatment group was based
on analysis of the human antibody responses to a number of
malaria antigens that have been tested in clinical trials
[26,27]. Based on the distribution of antibody responses for
each of the antigens, a sample size of ten volunteers per dose
cohort would permit detection of at least a 5-fold difference
in antibody concentration between groups using a Mann-
Whitney test, assuming a level of signiﬁcance of 0.05 and a
power of 0.80. Additionally, a group size of ten volunteers per
dose gives 0.80 probability for detecting one or more serious
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MSP142/Alhydrogel Vaccinesor severe adverse events that occurred with a probability of
0.15 per volunteer.
Randomization
This was an open-label, dose-escalating clinical trial and no
randomization procedure was utilized to assign volunteers to
dose cohort. Temporal staggering was used to assign
volunteers to dose cohorts. Volunteers were alternately
assigned to receive either the MSP142-FVO/Alhydrogel or
MSP142-3D7/Alhydrogel vaccine after enrollment in a dose
cohort. Dose-escalation occurred only after safety data up to
and including day 35 post-ﬁrst vaccination; 7 d post-second
vaccination was reviewed by the safety monitoring commit-
tee.
Statistical Methods
The frequency of adverse events was summarized and
stratiﬁed by dose cohort. Dose effects (on adverse events
and on antibody response) were tested for using exact two-
sided Jonckheere-Terpstra tests, and comparisons across the
vaccinations within each dose cohort were compared using
McNemar’s test (SAS version 9.1, SAS Institute, http://www.sas.
com). Tests of paired ELISA results (e.g., comparing day 0 to
day 42 responses or comparing homologous to heterologous
responses) were done by the Wilcoxon signed rank test using
all available pairs. Conﬁdence intervals for paired ELISA
results were done by paired t-test. For the GIA, conﬁdence
intervals were done using t-distributions. Either the UNI-
STAT statistical package (version 5.5) or R (version 2.4.0 of R,
using the exactRankTests package, version 0.8–15) were used
for these analyses, and p-values of less than or equal to 0.05
were considered signiﬁcant.
RESULTS
Participant Flow
This study was conducted from June 2004 to November 2005.
Sixty volunteers (26 male and 34 female) were enrolled. The
age range was 18–48 y (median, 27). Nine volunteers (15%)
identiﬁed themselves as African American, three (5%) as
Hispanic, and 48 (80%) as Caucasian. Fifty-four volunteers
received all three vaccinations as scheduled (Figure 1). No
volunteer was withdrawn due to a vaccine-related adverse
event.
Outcomes and Estimations
Safety and tolerability data. Both the MSP142-FVO/Alhy-
drogel and the MSP142-3D7/Alhydrogel vaccines were safe
and well tolerated (Tables 1 and 2). The most common
reported adverse event was pain at the injection site. The
majority of injection site reactions were graded as mild (98%
for the MSP142-FVO vaccine and 94% for the MSP142-3D7
vaccine), and none were graded as severe. Erythema,
induration, and pruritus also occurred at low frequencies
(10%–25%). The most common solicited systemic adverse
events were headache and fatigue. No immediate hyper-
sensitivity reactions were observed and no serious adverse
events occurred that were attributed to the vaccine.
No effect was found between dose and severity of the
highest-grade adverse event observed for each volunteer
(both vaccines: p ¼ 0.762; MSP142-FVO/Alhydrogel vaccine
only: p ¼ 0.764; or MSP142-3D7/Alhydrogel vaccine only: p ¼
0.475). Additionally, no signiﬁcant dose effect was found
when looking at the number of local adverse events per
volunteer relative to the dose (both vaccines: p ¼ 0.601,
MSP142-FVO/Alhydrogel vaccine only: p ¼ 0.594; or MSP142-
3D7/Alhydrogel vaccine only: p¼0.808). Local reactions were
more frequent following the ﬁrst vaccination compared to
either the second (odds¼20:5, p¼0.004) or third vaccinations
(odds ¼ 21:5, p ¼ 0.0025).
One volunteer in the 80-lg MSP142-3D7/Alhydrogel vaccine
group developed pain at the injection site following the third
vaccination which lasted for 4 d. After the third vaccination, 8
d later, the volunteer complained of left upper extremity/
shoulder pain which was rated as severe. The volunteer was
evaluated in a local emergency room with a left upper
extremity venous Doppler, plain ﬁlm x-ray, and laboratory
testing. The physical examination and test results were
negative. The ﬁnal diagnosis was an atypical injection site
reaction/musculoskeletal pain based on the temporal associ-
ation with vaccination and exclusion of other etiologies.
Antibody assessment by ELISA. Antibody levels to both the
MSP142-FVO and MSP142-3D7 antigens were measured by
ELISA on sera obtained on days 0, 14, 28, 42, 120, 180, 194,
270, and 364. A subset of the sera samples were assessed for
antibodies recognizing regions of the MSP142 protein: anti-
MSP119-FVO and anti-MSP119-3D7 antibodies (days 0, 42,
194, and 270) and anti-MSP133-FVO and anti-MSP133-3D7
antibodies (day 0 and 194).
Figure 2 shows the anti-MSP142 antibodies to the homol-
ogous protein in each dose of the MSP142-FVO/Alhydrogel
and MSP142-3D7/Alhydrogel vaccinated groups. Elevated
MSP142-speciﬁc antibody levels were observed 2 wk following
the second vaccination (day 42), when compared to prevacci-
nation levels (p , 0.001 for both vaccines tested on either
homologous or heterologous antigen). These antibodies
diminished over time and in many volunteers had returned
to near background levels by the time of the third
vaccination. After the third vaccination (day 194), 2 wk later,
a recall response was observed with an increase in speciﬁc
anti-MSP142 antibodies to levels greater than or equal to
those observed after two vaccinations (p , 0.001 for both
vaccines tested on either homologous or heterologous
antigen). The elevated MSP142-speciﬁc antibody levels ob-
served on day 194 diminished with time, but 6 mo after the
third vaccination, low-level speciﬁc antibody was still
detectable.
Speciﬁc antibody levels following the third vaccination
were greater than those observed after the second vaccina-
tion for all dose cohorts. The number of responders in all
groups also increased with eight of 30 and ten of 30
responders after two vaccinations and 20 of 27 and 22 of 27
responders after three vaccinations with MSP142-FVO/Alhy-
drogel and MSP142-3D7/Alhydrogel, respectively. The effect
of vaccine dose on speciﬁc antibody responses to either
MSP142-FVO or the MSP142-3D7 protein on day 42 and 194
was evaluated for both of the MSP142 vaccines. The day 42
ELISA of MSP142-FVO/Alhydrogel on the MSP142-FVO
antigen was the only signiﬁcant dose effect (p ¼ 0.044), and
this effect was only just signiﬁcant. For the remainder of the
comparisons, no signiﬁcant correlation between vaccine dose
and antibody response was detected.
The MSP142-FVO/Alhydrogel and MSP142-3D7/Alhydrogel
vaccines were equally immunogenic. Among recipients of
www.plosclinicaltrials.org April | 2007 | e12 0006
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MSP142/Alhydrogel VaccinesFigure 2. Kinetics of Homologous Anti-MSP142 Antibody Responses Following MSP142-FVO/Alhydrogel (Left) and MSP142-3D7/Alhydrogel (Right)
Vaccination
Antibody ELISA units to the immunizing antigen for each individual are shown by the scatter plots. The bars represent the group arithmetic means. Volunteers
were vaccinated intramuscularly on days 0, 28, and 180 (indicated by arrows) with 5 lg (top), 20 lg (middle), or 80 lg (bottom) dose of vaccine. ELISA units are
expressed relative to a MSP1 standard serum pool. A response was defined as .50 ELISA units.
doi:10.1371/journal.pctr.0020012.g002
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MSP142/Alhydrogel Vaccineseither vaccine, there was some evidence of MSP142 strain
speciﬁcity in the antibody response of sera from days 42 or
194 (Figure 3); sera recognized the homologous (i.e.,
immunizing) antigen better than heterologous antigen at
day 194 (p , 0.001) but not at day 42 (p¼0.642). However, in
both cases the mean absolute difference in ELISA units is
small (day 42:  3 units, 95% conﬁdence interval:  19 to 13;
day 194: 58 units, 95% conﬁdence interval: 10 to 106).
Vaccination with MSP142 generated antibodies that recog-
nized the C-terminal domain of the MSP119 protein. The
antibodies speciﬁc to MSP119 were observed following the
second vaccination (day 42), increased following the third
vaccination, and remained detectable 90 d after the third
vaccination (day 270) (Figure 4). The only signiﬁcant relation-
ship between dose and anti-MSP119 antibody levels was for
the MSP142-FVO/Alhydrogel vaccine at day 42 (p ¼ 0.0238
when tested on MSP119-FVO protein and p ¼ 0.0378 on
MSP119-3D7 protein).
By day 42, individuals vaccinated with MSP142-FVO/
Alhydrogel or MSP142-3D7/Alhydrogel generated similar
levels of antibodies that recognized the homologous and
heterologous MSP119 proteins (Wilcoxon signed rank test, p
. 0.05). Comparison of the MSP119 antibody reactivity in sera
from days 194 and 270 of the MSP142-FVO vaccine showed no
difference between homologous and heterologous MSP119
proteins. But within the MSP142-3D7 vaccine, individual sera
collected on days 194 and 270 recognized MSP119-3D7
(homologous) protein better than MSP119-FVO (heterolo-
gous) protein (Wilcoxon signed rank test, p , 0.004 for each
day); the absolute difference in ELISA units was very small.
For both vaccines, a strong association between MSP142
antibodies and MSP119 antibodies was observed after day 194
(Spearman rank correlation: r . 0.94 and p , 0.0001 for all
homologous comparisons on days 194 and 270).
Following three vaccinations (day 194), a small increase in
antibodies to the homologous MSP133 protein was observed
in both the MSP142-FVO/Alhydrogel and MSP142-3D7/Alhy-
drogel vaccinated groups (Figure 5). Increased antibody
response to the heterologous MSP133 protein was not
observed. There was no correlation between vaccine dose
and homologous anti-MSP133 antibody levels. For both
vaccines, a signiﬁcant association between homologous
MSP142 and MSP133 antibodies was observed (MSP142-3D7/
Alhydrogel Spearman rank correlation, r ¼ 0.89, p , 0.0001
and MSP142-FVO/Alhydrogel Spearman rank correlation, r ¼
0.78, p , 0.0001). A correlation was also observed between
homologous anti-MSP133 and anti-MSP119 antibodies (Spear-
man rank correlation: FVO proteins, r¼0.73, p , 0.0001 and
3D7 proteins, r ¼ 0.84, p , 0.0001).
IgG subclass analysis of day 194 sera. Sera obtained at day
194 with MSP142-speciﬁc antibody units greater than 500
were analyzed by a multiplex Luminex system for the
proportion of MSP142-speciﬁc IgG1, IgG2, IgG3, and IgG4
antibodies. For volunteers vaccinated with either MSP142-
FVO/Alhydrogel (n¼7) or MSP142-3D7/Alhydrogel (n¼8), the
majority of the MSP142 antibodies were IgG1 (Figure 6),
consistent with the IgG subclass proﬁle of an Alhydrogel-
based vaccine.
Parasite GIA. The GIA is designed to measure the biologic
function of the antibodies by determining whether anti-
MSP142 antibodies can inhibit merozoite invasion into
erythrocytes. Analysis of preclinical immunogenicity studies
in a variety of animals has shown a positive correlation
between anti-MSP142 antibody levels and inhibition of para-
site growth in vitro [28] (L. B. Martin, et al., unpublished
data). Immunoglobulin G (IgG) was puriﬁed from day 0 and
42 sera of the 80-lg dose cohorts. Subsequently, IgG was also
puriﬁed from days 180 and 194 sera of all volunteers with an
anti-MSP142 ELISA level on day 194 greater than 500
antibody units (n ¼ 7 from the MSP142-FVO/Alhydrogel and
n ¼ 8 from the MSP142-3D7/Alhydrogel). The IgG was tested
for activity in the GIA using both the FVO and 3D7 P.
falciparum lines.
None of the IgG samples puriﬁed from volunteer sera
either on day 42 or 194 showed growth inhibitory activity
higher than 20% (unpublished data) when tested at an IgG
concentration in the assay of 2.5 mg/mL (approximately 25%
of in vivo levels). Puriﬁed IgG from day 194 samples with an
Figure 3. Comparison of MSP142-FVO and MSP142-3D7 Antibody Levels on (A) Day 42 and (B) Day 194 Sera from MSP142-FVO/Alhydrogel and MSP142-
3D7/Alhydrogel Vaccinated Individuals
Data for individual volunteers are shown by the scatter plots: 5-lg dose (circles), 20-lg dose (squares), and 80-lg dose (diamonds); closed symbols are the
MSP142-FVO/Alhydrogel vaccine and open symbols are the MSP142-3D7/Alhdyrogel vaccine. Volunteers were vaccinated IM on days 0, 28, and 180 with the
indicated dose of vaccine. ELISA units are expressed relative to a MSP1 standard serum pool.
doi:10.1371/journal.pctr.0020012.g003
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MSP142/Alhydrogel VaccinesELISA concentration of .500 units were also tested at a
concentration of 5 mg/mL (ELISA units in the assay ranged
from 200–1,400 units) and there was small but signiﬁcant
activity (GIA on FVO parasites: mean 11.9, 95% conﬁdence
interval: 9.4 to 14.4; GIA on 3D7 parasites mean: 3.6, 95%
conﬁdence interval 2.1 to 5.1). Signiﬁcant correlations were
obtained between the level of anti-MSP142 antibody on day
194 and percent growth inhibition of both the FVO and 3D7
parasite lines (Spearman rank correlation, r¼0.56, p¼0.0177
and r ¼ 0.8394, p ¼ 0.0001, respectively).
Parasite IFA. The ability of 53 of 54 volunteer’s sera
obtained at day 0 and day 194 to recognize the native MSP1
protein on P. falciparum FVO and 3D7 parasites was evaluated.
Sera from all individuals (diluted 1:100) were evaluated for
intensity of staining and the staining pattern of parasitized
RBC.
Of the samples tested, minimal diffuse ﬂuorescence was
detected in the day 0 serum samples. After three vaccinations
with MSP142-FVO/Alhydrogel or MSP142-3D7/Alhydrogel, half
of the day 194 serum samples (27 of 54 sera on FVO parasites
and 24 of 54 on 3D7 parasites) exhibited positive ﬂuorescence
staining of trophozoites (characteristic surface pattern) and
schizont (morphology of grape-like clusters) blood-stage
parasites as well as surface pattern of free merozoites
(unpublished data). Regardless of the vaccine, the immune
sera recognized the homologous and the heterologous native
parasite antigen similarly (Wilcoxon signed rank test, p ¼
Figure 4. Homologous and Heterologous Anti-MSP119 Antibody Levels
Following MSP142-FVO/Alhydrogel (A) and MSP142-3D7/Alhydrogel (B)
Vaccination
Antibody ELISA units to the immunizing and heterologous forms of MSP119
for each volunteer are shown by the scatter plot. The bars represent the
group arithmetic means. Volunteers were vaccinated IM on days 0, 28, and
180 with 5-, 20-, or 80-lg dose of the indicated vaccine. ELISA units are
expressed relative to a MSP1 standard serum pool.
doi:10.1371/journal.pctr.0020012.g004
Figure 5. Homologous and Heterologous Anti-MSP133 Antibody Levels
Following Three Vaccinations with MSP142-FVO/Alhydrogel (A) and
MSP142-3D7/Alhydrogel (B)
Optical density in the standard ELISA assay to the immunizing and
heterologous form of MSP133 for each volunteer serum diluted 1:500 is
shown by the scatter plots. The bars represent the group arithmetic means.
Volunteers were vaccinated IM on days 0, 28, and 180 with 5-, 20-, or 80-lg
dose of the indicated vaccine.
doi:10.1371/journal.pctr.0020012.g005
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MSP142/Alhydrogel Vaccines0.6509). Intensity of staining in the IFA correlated with
MSP142 ELISA units at day 194 (Spearman rank correlation, r
¼0.7628 with p , 0.0001 for FVO parasites and ELISA, and r
¼0.7726 with p , 0.0001 ELISA for 3D7 parasites and ELISA).
DISCUSSION
Interpretation
This study compared the safety and immunogenicity of two
dimorphic forms of the MSP142 antigen in humans. The
results of this trial demonstrate both MSP142-FVO/Alhydrogel
and MSP142-3D7/Alhydrogel are safe when administered to
healthy adult malaria-naı ¨ve volunteers. The safety proﬁle of
these blood-stage vaccines supports the further development
of a vaccine containing both proteins, referred to as MSP142-
C1.
An important secondary objective was to compare the
ability of the MSP142-FVO and MSP142-3D7 vaccines to elicit
speciﬁc antibody responses in malaria-naı ¨ve individuals after
primary immunization and revaccination. For both MSP142-
FVO/Alhydrogel and MSP142-3D7/Alhydrogel groups, no
antibody response to the homologous immunogen was
detected 2 wk after the ﬁrst vaccination, but an increase in
speciﬁc antibody was observed in volunteers after the second
and third immunizations of either vaccines. These observa-
tions suggest that the initial immunizations induced B cell
memory and revaccination boosted memory B cell responses.
The proportion of responders in all dose cohorts increased
markedly after each vaccination.
Generalizability
MSP142-FVO and MSP142-3D7 polypeptides provide multiple
B cell and T cell epitopes [15,16], and their amino acid
compositions differ by greater than 50%, predominantly in
the N-terminal 33-kDa region. The highly conserved C-
terminal 19-kDa domain of MSP142 is preferentially recog-
nized by antibodies. Antibodies to MSP119 prevent invasion
and growth of the parasites in erythrocytes [29–31], and are
also associated with protection against severe malaria [32–37].
Several T cell epitopes have been mapped to the dimorphic
N-terminal 33-kDa region [16].
Preclinical studies showed overall antibody responses to
MSP142-FVO were greater than MSP142-3D7. Although anti-
bodies generated in response to vaccination cross-reacted
with both forms of the protein, they preferentially recognized
the homologous protein by ELISA and the homologous
parasite by GIA (L. B. Martin, et al., unpublished data). In
contrast, data from this clinical trial showed MSP142-FVO/
Alhydrogel and MSP142-3D7/Alhydrogel were equally immu-
nogenic, and the antibodies elicited by each vaccine
recognized the homologous and heterologous MSP142 re-
combinant proteins and native parasite proteins qualitatively
similarly.
Antibody levels to MSP142 protein correlated with antibody
levels to both the MSP119 and to MSP133 proteins. These data
indicate that both the conserved 19-kDa domain and the
dimorphic 33-kDa region of MSP142 are recognized by B cells
and stimulate antibody responses. However, the majority of
the antibodies induced by vaccination were targeted to the
conserved domain, MSP119. The biological impact of the low
levels of anti-MSP133 antibodies to the homologous protein is
unknown. These data suggest that there is little difference in
the antibody response generated by the dimorphic forms of
MSP142. The data from this study are in contrast to that
obtained following vaccination with FMP1/AS02A where the
resulting antibodies preferentially recognized the homolo-
gous antigen in malaria-naı ¨ve [19] and malaria-experienced
[20,38] adults.
The nature of the MSP142-speciﬁc antibody response and T
cell immune response generated in the volunteers of the
current study were found to be qualitatively different.
Antibodies generated following vaccination with either
MSP142-FVO/Alhydrogel or MSP142-3D7/Alhydrogel were
highly cross-reactive in their ability to recognize the FVO
or 3D7 form of MSP142 and MSP119, whereas the low-level
antibody to the dimorphic MSP133 region as allele-speciﬁc.
This suggests limited strain speciﬁcity in the majority of the
antibody response. In contrast, cytokine ELISPOT analysis of
MSP142-speciﬁc T cell responses revealed a strong preference
toward the immunizing antigen with limited activation by the
alternate form of MSP142 (C. Huaman, et al., unpublished
data). The epitopes responsible for the cytokine production
were localized to the N-terminal 33-kDa region of MSP142.
This suggests that the development of a memory response
following MSP142 vaccination may require the inclusion of
the relevant T-helper epitopes from the dimorphic region.
While there is considerable experimental support for the
choice of MSP142 as a vaccine candidate, the selection of this
protein is potentially complicated by the dimorphism
observed in different ﬁeld isolates [39]. The levels of cellular
and humoral immune responses required to protect against
severe malaria are unknown. Thus, the requirements for a
blood-stage vaccine to sensitize and potentiate appropriate
immune responses that would protect individuals, particu-
larly children, against malaria in areas of varying endemicity
are even more speculative. Dramatically different immune
responses have been reported in adult volunteers vaccinated
Figure 6. IgG Subclass Analysis of Antibodies Generated by Vaccination
with MSP142-FVO/Alhydrogel and MSP142-3D7/Alhydrogel
Day 194 serum samples from seven volunteers vaccinated with MSP142-FVO/
Alhydrogel and eight with MSP142-3D7/Alhydrogel were assayed for IgG
subclasses against the immunizing antigen. Serum samples were diluted
1:100 and mixed with beads coupled with homologous MSP142 antigen.
Mouse anti-human IgG isotypes and donkey anti-mouse-IgG PE labeled was
added to develop the reaction. The mean fluorescence intensity of specific
IgG subclasses to MSP142 is presented.
doi:10.1371/journal.pctr.0020012.g006
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with FMP1/AS02A in Mali and Kenya, areas of Africa that vary
in parasite transmission [21]. This suggests that in a malaria-
endemic area where multiple allelic forms of the parasite are
present, a combination MSP142-FVO and MSP142-3D7 vac-
cine (MSP142-C1) to prime for or boost immune responses
may be required.
Overall Evidence
The anti-MSP142 antibodies induced by either MSP142
vaccine recognized the native parasite protein, as shown by
immunoﬂuorescence microscopy, but did not give high levels
of activity in the in vitro parasite growth inhibition assay at
the concentrations tested. Vaccine-induced MSP142 anti-
bodies from preclinical studies in animals have shown
substantial GIA activity, but generation of this activity
requires either multiple vaccinations or formulation with
other adjuvants [28,40] (L. B. Martin, et al., unpublished data).
Biochemical stability studies and in vivo potency studies
conducted over the course of the clinical trial have conﬁrmed
that the antigens in each of the formulations retained
conformation. Therefore, it was concluded that the two
MSP142/Alhydrogel formulations are not sufﬁciently immu-
nogenic to generate an antibody response able to block
parasite invasion of erythrocytes detectable by the in vitro
growth inhibition assay. On the basis of the correlation
observed, it is estimated that at least a 10-fold higher
antibody response will be needed before substantial GIA
activity will be observed. Thus, if in vitro parasite GIA is
found to be a good predictor of vaccine-induced protection
of infants and children from malaria, then enhancing the
immunogenicity of Alhydrogel-formulated MSP142 will be an
important step toward developing a useful vaccine. MVDB is
pursuing the addition of immunostimulants to the Alhydro-
gel formulation of MSP142-C1, the combination of MSP142-
FVO and MSP142-3D7, to elicit higher immune responses in
humans.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020012.sd001 (50 KB DOC).
Trial Protocol Version 7.1
Found at doi:10.1371/journal.pctr.0020012.sd002 (601 KB DOC).
Accession Numbers
EcMSP142-FVO (AY343089) and EcMSP142-3D7 (DQ414722) were
expressed as histidine-tagged fusion proteins from synthetic genes
from GenBank (http://www.ncbi.nlm.nih.gov/Genbank). Also included
are plasmids EcMSP133-FVO (DQ923123) and EcMSP133-3D7
(DQ923124).
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